Prescription et surveillance d’antipsychotiques chez les patients âgés souffrant de schizophrénie : pratiques des psychiatres et leurs déterminants

Jalenques, Isabelle; Ortega, V.; Legrand, Guillaume; Auclair, C.

doi:10.1016/j.encep.2015.05.004

Cited by 2 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of such medications in this age group is most of the times done off-label, as most of the evidence about their effectiveness and safety was extrapolated from younger adults. They can be used in the elderly to manage BPSD, which may affect up to 90% of the patients (1,7). A systematic review found that risperidone, olanzapine, and aripiprazole showed greater efficacy than quetiapine, including the more severe cases.…”

Section: Introductionmentioning

confidence: 99%

Identification of a Set of Patient-Related Features to Foster Safe Prescribing of Specific Antipsychotics in the Elderly With Dementia

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Identification of a Set of Patient-Related Features to Foster Safe Prescribing of Specific Antipsychotics in the Elderly With Dementia

et al. 2020

View full text Add to dashboard Cite

show abstract

The impact of antipsychotics as a risk factor for thromboembolism

Ogłodek

Just

Grzesińska³

et al. 2018

Pharmacological Reports

View full text Add to dashboard Cite

Patients with schizophrenia are predisposed toward developing cardiovascular disease. Although neuroleptics affect the cardiovascular system, it is also important to consider the consequences of the disease itself such as lower physical activity due to living on disability pension, inadequate nutrition, and/or nicotine addiction, being more common among patients with schizophrenia versus the general population. All these factors combined lead to an increased risk of death caused by cardiovascular conditions in schizophrenic patients. Individuals receiving typical antipsychotic drugs have been reported to have elevated concentrations of antiphospholipid antibodies, including anticoagulants and anticardiolipin antibodies. The presence of both antibodies is associated with an increased risk for thromboembolism. It is also likely that mental illness is accompanied by increased procoagulant activity. Patients with acute psychosis have been shown to have a statistically significant increase in the concentrations of D-dimer, P-selectin, and in the expression of platelet glycoprotein IIb/IIIa receptors. Learning about causes and mechanisms of venous thromboembolism could help to reduce or neutralize the adverse effects of antipsychotic treatment and facilitate the identification of appropriate markers necessary to monitor changes and provide preventive care against hazardous and potentially fatal complications such as deep venous thrombosis and pulmonary embolism. Before atypical neuroleptic treatment is administered to hospitalized patients, all possible risk factors for thromboembolism should be considered to allow the application of lower risk drugs. Also, other preventive measures should be taken into account, including hydration, compression stockings, regular exercise of lower extremities, and low-molecular-weight heparin injections.

show abstract

Prescription et surveillance d’antipsychotiques chez les patients âgés souffrant de schizophrénie : pratiques des psychiatres et leurs déterminants

Cited by 2 publications

References 24 publications

Identification of a Set of Patient-Related Features to Foster Safe Prescribing of Specific Antipsychotics in the Elderly With Dementia

Identification of a Set of Patient-Related Features to Foster Safe Prescribing of Specific Antipsychotics in the Elderly With Dementia

The impact of antipsychotics as a risk factor for thromboembolism

Contact Info

Product

Resources

About